We make a urine test that helps women get pregnant.
Key people at Zergo.
Zergo was founded in 2018 by Thomas Dunlop (Founder) and Noah Debrincat (Founder).
Key people at Zergo.
Zergo was founded in 2018 by Thomas Dunlop (Founder) and Noah Debrincat (Founder).
Zergo is a health technology company that develops a urine test designed to help women conceive by providing insights into fertility. The product targets women trying to get pregnant, offering a non-invasive, accessible way to monitor fertility status and optimize timing for conception. Zergo’s solution addresses the challenge many women face in understanding their fertility window, aiming to improve pregnancy success rates through better-informed decisions. The company has shown early traction by pivoting from its previous identity as SannTek Labs (which developed a breathalyzer for cannabis) to focus on fertility, reflecting a strategic shift toward reproductive health technology[1].
Zergo was originally known as SannTek Labs, a startup that created a breathalyzer for detecting cannabis use. The founders transitioned the company’s focus to fertility technology, inspired by the growing demand for accessible fertility solutions and the limitations of existing methods. This pivot led to the development of their urine test for women seeking to conceive. The founding team leveraged their prior experience in diagnostic testing to innovate in the fertility space, aiming to simplify and democratize fertility monitoring. Early milestones include successful product development and initial market interest, positioning Zergo as a promising player in the fertility tech sector[1].
Zergo is part of a broader trend toward consumer-driven fertility health technology, which includes home testing kits and AI-powered fertility insights. This trend is driven by rising awareness of fertility challenges, delayed childbearing, and a desire for privacy and convenience in reproductive health management. The timing is favorable due to increased acceptance of at-home diagnostics post-pandemic and growing investment in women’s health tech. Zergo contributes to the ecosystem by expanding options for fertility monitoring, potentially reducing barriers to conception and complementing clinical fertility treatments[1][2].
Looking ahead, Zergo is well-positioned to capitalize on the expanding fertility tech market by enhancing its product capabilities, possibly integrating with digital health platforms or fertility coaching services. Trends such as personalized medicine, AI-driven health insights, and increasing consumer demand for fertility solutions will likely shape its growth trajectory. As fertility awareness continues to rise globally, Zergo’s influence could grow by empowering women with actionable fertility data, helping to improve conception outcomes and overall reproductive health management.
---
This overview highlights Zergo’s transition from a cannabis diagnostic startup to a fertility-focused company, its innovative urine test product, and its role in the evolving fertility tech landscape. The company’s future success will depend on its ability to scale, innovate, and integrate within the broader reproductive health ecosystem.
